International Journal of Medical and All Body Health Research  |  e-ISSN: 2582-8940  |  Double-Blind Peer Review  |  Open Access  |  CC BY-NC-SA 4.0

Current Issues
     2026:7/4

International Journal of Medical and All Body Health Research

e-ISSN: 2582-8940 | Open Access

Iatrogenic Esophageal Perforation After ERCP Early Recognition and Outcome Innovative Strategies High-Throughput Screening and Translational Approaches for Accelerated Therapeutic Development

Dr Karuna Sharma, Dr Sarveshwar

Resident, General Surgery, Pandit Bhagwat Dayal Sharma University of Health Sciences, Rohtak, Haryana, India

Article Information

Volume / Issue7 / 1 (January-March 2026)
Pages107-118
AccessOpen Access

Publication Timeline

  • Received20 November 2025
  • Accepted22 December 2025
  • Published

Full Text (PDF)

Open Access - Free to Download

Download Full Article (PDF) JATS XML

Abstract

Background: Iatrogenic esophageal perforation represents a catastrophic complication of endoscopic retrograde cholangiopancreatography with mortality rates reaching 10-25%, yet therapeutic options remain limited to surgical intervention and supportive care. The absence of targeted pharmacological therapies for tissue repair, infection prevention, and inflammation modulation in gastrointestinal perforations reflects broader challenges in pharmaceutical development, including prolonged discovery timelines averaging 12-15 years, high clinical attrition rates exceeding 90%, and inadequate translation of preclinical findings to clinical efficacy. Current drug discovery paradigms face substantial obstacles in identifying and validating therapeutic targets for acute surgical complications and developing agents that promote accelerated tissue healing while preventing septic complications. 
Aim: This article examines innovative pharmaceutical development strategies applicable to acute gastrointestinal injuries, linking clinical management of iatrogenic esophageal perforation with contemporary drug discovery approaches including high-throughput screening, computational target identification, and translational research frameworks. 
Discussion: Modern drug development increasingly employs high-throughput screening platforms evaluating millions of compounds against validated biological targets, structure-based drug design leveraging three-dimensional protein structures, and systems biology approaches identifying network-level therapeutic opportunities. Target identification through genomic and proteomic profiling, coupled with advanced preclinical models recapitulating human tissue injury and repair, enables more predictive assessment of clinical translation. Lead optimization employs multi-parameter approaches simultaneously enhancing potency, selectivity, and pharmaceutical properties. 
Impact: Implementation of accelerated development strategies demonstrates substantial reductions in discovery timelines and improved clinical success rates, particularly for repurposed therapeutics and precision medicine applications targeting specific patient populations or injury mechanisms. 
Outlook: Future advancement requires integration of artificial intelligence-driven compound prediction, patient-specific biomarker development, organoid-based disease modeling, and adaptive clinical trial designs to optimize therapeutic development for acute surgical complications and critical care applications.
 

Keywords

Drug DiscoveryPharmaceutical DevelopmentTranslational ResearchHigh-Throughput ScreeningLead OptimizationPrecision Medicine

References

  1. Brinster CJ, Singhal S, Lee L, Marshall MB, Kaiser LR, Kucharczuk JC. Evolving options in the management of esophageal perforation. Ann Thorac Surg. 2004;77(4):1475-1483. [Google Scholar][Crossref]
  2. Kaman L, Iqbal J, Kundil B, Kochhar R. Management of esophageal perforation in adults. Gastroenterol Res. 2010;3(6):235-244. [Google Scholar][Crossref]
  3. Søreide JA, Konradsson A, Sandvik OM, Øvrebø K, Viste A. Esophageal perforation: clinical patterns and outcomes from a patient cohort of Western Norway. Dig Surg. 2012;29(6):494-502. [Google Scholar][Crossref]
  4. Chirica M, Champault A, Dray X, Sulpice L, Munoz-Bongrand N, Sarfati E, et al. Esophageal perforations. J Visc Surg. 2010;147(3):e117-e128. [Google Scholar][Crossref]
  5. Biancari F, D'Andrea V, Paone R, Di Marco C, Savino G, Koivukangas V, et al. Current treatment and outcome of esophageal perforations in adults: systematic review and meta-analysis of 75 studies. World J Surg. 2013;37(5):1051-1059. [Google Scholar][Crossref]
  6. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of research and development costs. J Health Econ. 2016;47:20-33. [Google Scholar][Crossref]
  7. Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat Biotechnol. 2014;32(1):40-51. [Google Scholar][Crossref]
  8. Arrowsmith J, Miller P. Trial watch: phase II and phase III attrition rates 2011-2012. Nat Rev Drug Discov. 2013;12(8):569. [Google Scholar][Crossref]
  9. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve research and development productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010;9(3):203-214. [Google Scholar][Crossref]
  10. Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical research and development efficiency. Nat Rev Drug Discov. 2012;11(3):191-200. [Google Scholar][Crossref]
  11. Guo JL, White PS, Bradfield JP. Genome-wide association studies in pharmacogenomics. Pharmacogenomics. 2011;12(7):1027-1037. [Google Scholar][Crossref]
  12. Finan C, Gaulton A, Kruger FA, Lumbers RT, Shah T, Engmann J, et al. The druggable genome and support for target identification and validation in drug development. Sci Transl Med. 2017;9(383):eaag1166. [Google Scholar][Crossref]
  13. Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4(11):682-690. [Google Scholar][Crossref]
  14. Macarron R, Banks MN, Bojanic D, Burns DJ, Cirovic DA, Garyantes T, et al. Impact of high-throughput screening in biomedical research. Nat Rev Drug Discov. 2011;10(3):188-195. [Google Scholar][Crossref]
  15. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1-3):3-26. [Google Scholar][Crossref]
  16. Baell JB, Holloway GA. New substructure filters for removal of pan assay interference compounds from screening libraries. J Med Chem. 2010;53(7):2719-2740. [Google Scholar][Crossref]
  17. Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov. 2011;10(7):507-519. [Google Scholar][Crossref]
  18. Waring MJ, Arrowsmith J, Leach AR, Leeson PD, Mandrell S, Owen RM, et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov. 2015;14(7):475-486. [Google Scholar][Crossref]
  19. Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov. 2014;13(6):419-431. [Google Scholar][Crossref]
  20. Whitebread S, Hamon J, Bojanic D, Urban L. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discov Today. 2005;10(21):1421-1433. [Google Scholar][Crossref]
  21. Gussow AB, Park AE, Borges AL, Shmakov SA, Makarova KS, Wolf YI, et al. Machine-learning approach expands the repertoire of anti-CRISPR protein families. Nat Commun. 2020;11(1):3784. [Google Scholar][Crossref]
  22. Schneider P, Walters WP, Plowright AT, Sieroka N, Listgarten J, Goodnow RA Jr, et al. Rethinking drug design in the artificial intelligence era. Nat Rev Drug Discov. 2020;19(5):353-364. [Google Scholar][Crossref]
  23. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463-477. [Google Scholar][Crossref]
  24. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today. 2019;24(3):773-780. [Google Scholar][Crossref]
  25. Takebe T, Sekine K, Enomura M, Koike H, Kimura M, Ogaeri T, et al. Vascularized and functional human liver from an iPSC-derived organ bud transplant. Nature. 2013;499(7459):481-484. [Google Scholar][Crossref]
  26. Huh D, Matthews BD, Mammoto A, Montoya-Zavala M, Hsin HY, Ingber DE. Reconstituting organ-level lung functions on a chip. Science. 2010;328(5986):1662-1666. [Google Scholar][Crossref]
  27. Clevers H. Modeling development and disease with organoids. Cell. 2016;165(7):1586-1597. [Google Scholar][Crossref]
  28. Sachs N, Papaspyropoulos A, Zomer-van Ommen DD, Heo I, Böttinger L, Klay D, et al. Long-term expanding human airway organoids for disease modeling. EMBO J. 2019;38(4):e100300. [Google Scholar][Crossref]
  29. Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. Science. 2014;345(6194):1247125. [Google Scholar][Crossref]
  30. Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med. 2017;377(1):62-70. [Google Scholar][Crossref]
  31. Berry SM, Connor JT, Lewis RJ. The platform trial: an efficient strategy for evaluating multiple treatments. JAMA. 2015;313(16):1619-1620. [Google Scholar][Crossref]
  32. Ford I, Norrie J. Pragmatic trials. N Engl J Med. 2016;375(5):454-463. [Google Scholar][Crossref]
  33. Bothwell LE, Greene JA, Podolsky SH, Jones DS. Assessing the gold standard--lessons from the history of RCTs. N Engl J Med. 2016;374(22):2175-2181. [Google Scholar][Crossref]
  34. Collins R, Bowman L, Landray M, Peto R. The magic of randomization versus the myth of real-world evidence. N Engl J Med. 2020;382(7):674-678. [Google Scholar][Crossref]
  35. Dowden H, Munro J. Trends in clinical success rates and therapeutic focus. Nat Rev Drug Discov. 2019;18(7):495-496. [Google Scholar][Crossref]
  36. Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market 2009 -2018. JAMA. 2020;323(9):844-853. [Google Scholar][Crossref]
  37. Dickson M, Gagnon JP. Key factors in the rising cost of new drug discovery and development. Nat Rev Drug International Journal of Medical and All Body Health Research www.allmedicaljournal.com Discov. 2004;3(5):417-429. [Google Scholar][Crossref]
  38. Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, et al. The support of human genetic evidence for approved drug indications. Nat Genet. 2015;47(8):856-860. [Google Scholar][Crossref]
  39. Sanseau P, Agarwal P, Barnes MR, Pastinen T, Richards JB, Cardon LR, et al. Use of genome-wide association studies for drug repositioning. Nat Biotechnol. 2012;30(4):317-320. [Google Scholar][Crossref]
  40. Pushkarna M, Sboner A, Elemento O, Cerione RA. Translational bioinformatics approach to combat cardiovascular disease and cancers. Prog Mol Biol Transl Sci. 2016;139:217-238. [Google Scholar][Crossref]

How to Cite

Sharma, K., & Sarveshwar (2026). Iatrogenic Esophageal Perforation After ERCP Early Recognition and Outcome Innovative Strategies High-Throughput Screening and Translational Approaches for Accelerated Therapeutic Development. International Journal of Medical and All Body Health Research, 7(1), 107-118. https://doi.org/10.54660/IJMBHR.2026.7.1.107-118

Sharma, Karuna, and Sarveshwar. "Iatrogenic Esophageal Perforation After ERCP Early Recognition and Outcome Innovative Strategies High-Throughput Screening and Translational Approaches for Accelerated Therapeutic Development." International Journal of Medical and All Body Health Research, vol. 7, no. 1, 2026, pp. 107-118. https://doi.org/10.54660/IJMBHR.2026.7.1.107-118.

Sharma, K. and Sarveshwar (2026) 'Iatrogenic Esophageal Perforation After ERCP Early Recognition and Outcome Innovative Strategies High-Throughput Screening and Translational Approaches for Accelerated Therapeutic Development', International Journal of Medical and All Body Health Research, 7(1), pp. 107-118. doi: 10.54660/IJMBHR.2026.7.1.107-118.

Sharma K, Sarveshwar. Iatrogenic Esophageal Perforation After ERCP Early Recognition and Outcome Innovative Strategies High-Throughput Screening and Translational Approaches for Accelerated Therapeutic Development. International Journal of Medical and All Body Health Research. 2026;7(1):107-118. doi:10.54660/IJMBHR.2026.7.1.107-118

Similar Articles

Share

Find this Article on

Google Scholar Semantic Scholar OpenAlex Scilit Crossref ResearchGate BASE

A newly published article may take a few days to appear on these services.